Terazosin

Bezeichnung:Terazosin

CAS-Nr63590-64-7

Englisch Name:Terazosin

CBNumberCB2285511

SummenformelC19H25N5O4

Molgewicht387.43

MOL-Datei63590-64-7.mol

Terazosin physikalisch-chemischer Eigenschaften

Schmelzpunkt	281-283°C
Siedepunkt	664.5±65.0 °C(Predicted)
Dichte	1.332±0.06 g/cm3(Predicted)
storage temp.	-20°C Freezer
Löslichkeit	H₂O: 25 mg/mL
pka	pKa (0.1N NaOH): 7.1(at 25℃)
Aggregatzustand	powder
Farbe	white to off-white
Wasserlöslichkeit	30.6mg/L(22.5 ºC)
BCS Class	1/3
InChIKey	VCKUSRYTPJJLNI-UHFFFAOYSA-N
CAS Datenbank	63590-64-7(CAS DataBase Reference)

Sicherheit

Kennzeichnung gefährlicher	Xn,Xi
R-Sätze:	22-36/37/38
S-Sätze:	26-36
WGK Germany	3
RTECS-Nr.	TK8044925

Gefahreninformationscode (GHS)

Terazosin Chemische Eigenschaften,Einsatz,Produktion Methoden

R-Sätze Betriebsanweisung:
R22:Gesundheitsschädlich beim Verschlucken.
R36/37/38:Reizt die Augen, die Atmungsorgane und die Haut.
S-Sätze Betriebsanweisung:
S26:Bei Berührung mit den Augen sofort gründlich mit Wasser abspülen und Arzt konsultieren.
S36:DE: Bei der Arbeit geeignete Schutzkleidung tragen.
Chemische Eigenschaften
White to Off-White Crystalline Powder
Verwenden
Terazosin is used for the same indications as is prazosin; however, it has the advantage of being able to be used once a day.
Verwenden
An α-1-adrenergicblocker related to prazosin.
Verwenden
An a-1-adrenergicblocker related to prazosin
Definition
ChEBI: Terazosin is a member of quinazolines, a member of piperazines, a member of furans and a primary amino compound. It has a role as an antineoplastic agent, an antihypertensive agent and an alpha-adrenergic antagonist.
Clinical Use
Alpha-adrenoceptor blocker:
Hypertension
Benign prostatic hyperplasia (BPH)
Synthese
Terazosin, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)- piperazine (12.2.13), only differs from prazosin in that the furyl radical is replaced with a tetrahydrofuryl radical. It is synthesized in exactly the same manner except using 1-(2-tetrahydrofuroyl)piperazine instead of 1-(2-furoyl)piperazine [48–51].
Arzneimittelwechselwirkung
Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Antidepressants: enhanced hypotensive effect with MAOIs.
Avanafil, vardenafil, sildenafil and tadalafil: enhanced hypotensive effect - avoid concomitant use.
Beta-blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect.
Calcium-channel blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect.
Diuretics: enhanced hypotensive effect; increased risk of first dose hypotensive effect.
Moxisylyte: possibly severe postural hypotension when used in combination.
Stoffwechsel
Terazosin is metabolised in the liver; one of the metabolites has antihypertensive activity.
Terazosin is excreted in faeces via the bile, and in the urine, as unchanged drug and metabolites.

Terazosin Upstream-Materialien And Downstream Produkte

Terazosin Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

63590-64-7, Terazosin Verwandte Suche:

Send Inquriy